Similarly, aromatase inhibitors may be less effective in postmenopausal women with obesity due to increased peripheral estrogen production [22]
The question of which specific GLP-1 medication to start with, and whether compounded or brand-name is the right fit, is worth discussing with a provider who specializes in this area
We dont have 20-year safety data for Retatrutide specifically
Despite FDA registration , they are not FDA approved , offer no medical care, lack clinical evidence for effectiveness, misuse GLP-1 terminology in marketing, and have mixed reviews with many users reporting no results
These highlights do not include all the information needed to use Victoza safely and effectively
After a median follow up of 3.1 years the MACE (Major Adverse Cardiovascular Events) endpoint was reduced by 14% (HR = 0.86, P=0.04 for superiority) (Figure 2)